FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
BMJ14h
Nomogram model for predicting medication adherence in patients with various mental disorders based on the Dryad database
Objective Treatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication ...
Neuroscience News1d
Schizophrenia Risks Tied to Psychedelic Use
A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...